Key result
Previous combination antiplatelet therapy before intracerebral hemorrhage was associated with higher in-hospital mortality versus no therapy.
Why the study?
Does previous use of antiplatelet therapy increase in-hospital mortality in patients with intracerebral hemorrhage?
Observational (n=82,576)
Yes
Does previous use of antiplatelet therapy increase in-hospital mortality in patients with intracerebral hemorrhage?
Answers are grounded in this paper and cite their sources.
Prior use of combination antiplatelet therapy, but not single antiplatelet therapy, is associated with increased in-hospital mortality in patients presenting with intracerebral hemorrhage.
BACKGROUND AND PURPOSE: Although the use of antiplatelet therapy (APT) is associated with the risk of intracerebral hemorrhage (ICH), there are limited data on prestroke APT and outcomes, particularly among patients on combination APT (CAPT). We hypothesized that the previous use of antiplatelet agents is associated with increased mortality in ICH. METHODS: We analyzed data of 82 576 patients with ICH who were not on oral anticoagulant therapy from 1574 Get with the Guidelines-Stroke hospitals between October 2012 and March 2016. Patients were categorized as not on APT, on single-APT (SAPT), and CAPT before hospital presentation with ICH. We described baseline characteristics, comorbidities, hospital characteristics and outcomes, overall and stratified by APT use. RESULTS: Before the diagnosis of ICH, 65.8% patients were not on APT, 29.5% patients were on SAPT, and 4.8% patients were on CAPT. There was an overall modest increased in-hospital mortality in the APT group versus no APT group (24% versus 23%; adjusted odds ratio, 1.05; 95% confidence interval, 1.01-1.10). Although patients on SAPT and CAPT were older and had higher risk profiles in terms of comorbidities, there was no significant difference in the in-hospital mortality among patients on SAPT versus those not on any APT (23% versus 23%; adjusted odds ratio, 1.01; 95% confidence interval, 0.97-1.05). However, in-hospital mortality was higher among those on CAPT versus those not on APT (30% versus 23%; adjusted odds ratio, 1.50; 95% confidence interval, 1.39-1.63). CONCLUSIONS: Our study suggests that among patients with ICH, previous use of CAPT, but not SAPT, was associated with higher risk for in-hospital mortality.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2017) conducted an observational in Intracerebral hemorrhage (n=82,576). Combination antiplatelet therapy (CAPT) vs. No antiplatelet therapy was evaluated on In-hospital mortality (adjusted OR 1.50, 95% CI 1.39-1.63). Previous combination antiplatelet therapy before intracerebral hemorrhage was associated with higher in-hospital mortality versus no therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: